biosimiar_wordcloudBiologic agents have been proven to be highly effective in treating inflammatory diseases; however, many health care plans restrict the use of these agents due to rising costs. In April 2016, the first biosimilar monoclonal antibody for inflammatory diseases, infliximab-dyyb, was approved by the FDA. Three additional biosimilars have been approved in the U.S. since and many others remain in developmental stages.

As with any newly approved treatment option, there are many important questions surrounding the details of biosimilars in treating inflammatory disease from clinicians and patients alike: What do the terms interchangeability and extrapolation mean for my practice? Are these agents as efficacious as their reference biologic?  How does the development and manufacture of a biosimilar compare to the original biologic? Can my patients expect to see significant cost savings?  How does a clinician even go about ordering biosimilar agents?

Patients have also reported a significant lack of knowledge among clinicians on the topic of biosimilars and how they may be utilized to treat their inflammatory disease, while also decreasing the much-needed cost of care.

CME Outfitters has created this Biosimilars Hub to provide much-needed education to clinicians and patients about these newly approved agents through an array of free online activities. The Biosimilars Hub offers clinicians the option to participate in short CME Snacks or an in-depth On-Demand webcast to find the answers to the above questions and equip themselves with the knowledge necessary to confidently explain the interchangeability, efficacy, and safety of biosimilars to patients with inflammatory diseases.

CME Outfitters Webcast (with recorded Q&A) 

Debating Interchangeability, Efficacy, and Safety of Biosimilars in the Management of Inflammatory Diseases

Tune into this CME Outfitters Webcast where Leonard Calabrese, DO answered questions received from participants on the various aspects of biosimilars. Gain valuable insights as Dr. Calabrese addresses real concerns and questions surrounding the use of biosimilars in the management of inflammatory diseases.

Note: Credit Is No Longer Available for This Activity

Participate Now!

CME Snacks

An Evolving Treatment Landscape for Inflammatory Disease: Involving Patients in the Discussion of Biosimilars

Involving the patient in the discussion surrounding the treatment and management of their disease is a vital part of achieving optimal outcomes. In this CME Snack, an expert faculty panel will discuss the various ways you can effectively engage the patient in the conversation regarding biosimilars and their treatment.

Watch Now!

An Evolving Treatment Landscape for Inflammatory Disease: The Role of Biosimilars in RA and IBD

What are the potential advantages of switching your patients with RA or IBD to a biosimilar? Are there any enhanced clinical benefits of biosimilar agents? What data exists to compare toxicity and immunogenicity of biosimilars to their reference agents? This CME Snack, featuring Dr. Calabrese and Dr. Cohen, focuses on the answers to these questions and more on treating your patients with rheumatoid arthritis and inflammatory bowel diseases.

Watch Now!

CME Outfitters On Demand

An Evolving Treatment Landscape for Inflammatory Disease: Debating Interchangeability, Efficacy, and Safety of Biosimilars

A significant gap exists in awareness and knowledge amongst health care providers on the topic of biosimilars, creating perceived barriers within clinical practices. It’s imperative that clinicians are well-versed on the data surrounding interchangeability, safety, and efficacy of biosimilar agents so that they may confidently select the optimal treatment plan for their patients. In this CME Outfitters On Demand activity, real patient responses are at the center of the conversation, with expert faculty highlight the patients’ concerns while engaging in an evidence-based discussion on a variety of aspects of biosimilars.

Watch Now!

Download These Free Biosimilar Infographics

What Is a Biosimilar?

Download Now

Biological Product Definitions

Download Now

Biosimilar Product Regulatory Review and Approval

Download Now

Prescribing Biosimilar Products

Download Now

Prescribing Interchangeable Products

Download Now

Biosimilar FAQs 

What is a biological product?

Biological products are regulated by the Food and Drug Administration (FDA) and are used to diagnose, prevent, treat, and cure diseases and medical conditions. Biological products are a diverse category of products and are generally large, complex molecules. These products may be produced through biotechnology in a living system, such as a microorganism, plant cell, or animal cell, and are often more difficult to characterize than small molecule drugs. There are many types of biological products approved for use in the United States, including therapeutic proteins (such as filgrastim), monoclonal antibodies (such as adalimumab), and vaccines (such as those for influenza and tetanus).

The nature of biological products, including the inherent variations that can result from the manufacturing process, can present challenges in characterizing and manufacturing these products that often do not exist in the development of small molecule drugs. Slight differences between manufactured lots of the same biological product (i.e., acceptable within-product variations) are normal and expected within the manufacturing process. As part of its review, FDA assesses the manufacturing process and the manufacturer’s strategy to control within-product variations. These control strategies are put in place to help ensure that manufacturers produce biological products with consistent clinical performance.

What is a reference product?

A reference product is the single biological product, already approved by FDA, against which a proposed biosimilar product is compared. A reference product is approved based on, among other things, a full complement of safety and effectiveness data. A proposed biosimilar product is compared to and evaluated against a reference product to ensure that the product is highly similar and has no clinically meaningful differences.

What is a biosimilar product?

A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. These two standards are described further below.

What does it mean to be “highly similar”?

A manufacturer developing a proposed biosimilar demonstrates that its product is highly similar to the reference product by extensively analyzing (i.e., characterizing) the structure and function of both the reference product and the proposed biosimilar. State-of-the-art technology is used to compare characteristics of the products, such as purity, chemical identity, and bioactivity. The manufacturer uses results from these comparative tests, along with other information, to demonstrate that the biosimilar is highly similar to the reference product.

Minor differences between the reference product and the proposed biosimilar product in clinically inactive components are acceptable. For example, these could include minor differences in the stabilizer or buffer minor differences between the reference product and the proposed biosimilar product in clinically inactive components are acceptable. For example, these could include minor differences in the stabilizer or buffer compared to what is used in the reference product. Any differences between the proposed biosimilar product and the reference product are carefully evaluated by FDA to ensure the biosimilar meets FDA’s high approval standards.

What does it mean to have “no clinically meaningful differences”?

As mentioned above, slight differences (i.e., acceptable within-product variations) are expected during the manufacturing process for biological products, regardless of whether the product is a biosimilar or a reference product. For both reference products and biosimilars, lot-to-lot differences (i.e., acceptable within-product differences) are carefully controlled and monitored.

What is an interchangeable product?

An interchangeable product is a biosimilar product that meets additional requirements outlined by the Biologics Price Competition and Innovation Act. As part of fulfilling these additional requirements, information is needed to show that an interchangeable product is expected to produce the same clinical result as the reference product in any given patient. Also, for products administered to a patient more than once, the risk in terms of safety and reduced efficacy of switching back and forth between an interchangeable product and a reference product will have been evaluated.

An interchangeable product may be substituted for the reference product without the involvement of the prescriber. FDA’s high standards for approval should assure health care providers that they can be confident in the safety and effectiveness of an interchangeable product, just as they would be for an FDA-approved reference product.

What is the difference between a biosimilar and an interchangeable product?

As mentioned above, an interchangeable product, in addition to being biosimilar, meets additional requirements based on further evaluation and testing of the product. A manufacturer of a proposed interchangeable product will need to provide additional information to show that an interchangeable product is expected to produce the same clinical result as the reference product in any given patient. Also, for a product that is administered to a patient more than once, a manufacturer will need to provide data and information to evaluate the risk, in terms of safety and decreased efficacy, of alternating or switching between the products.

As a result, a product approved as an interchangeable product means that FDA has concluded it may be substituted for the reference product without consulting the prescriber. For example, say a patient self-administers a biological product by injection to treat their rheumatoid arthritis. To receive the biosimilar instead of the reference product, the patient may need a prescription from a healthcare prescriber written specifically for that biosimilar. However, once a product is approved by FDA as interchangeable, the patient may be able to take a prescription for the reference product to the pharmacy and, depending on the state, the pharmacist could substitute the interchangeable product for the reference product without consulting the prescriber. Note that pharmacy laws and practices vary from state to state.

FDA undertakes a rigorous and thorough evaluation to ensure that all products, including biosimilar and interchangeable products, meet the Agency’s high standards for approval.

Are biosimilars the same as generic drugs?

Biosimilars and generic drugs are versions of brand-name drugs and may offer more affordable treatment options to patients. Biosimilars and generics are each approved through different abbreviated pathways that avoid duplicating costly clinical trials. But biosimilars are not generics, and there are important differences between biosimilars and generic drugs.

For example, the active ingredients of generic drugs are the same as those of brand-name drugs. In addition, the manufacturer of a generic drug must demonstrate that the generic is bioequivalent to the brand name drug.

By contrast, biosimilar manufacturers must demonstrate that the biosimilar is highly similar to the reference product, except for minor differences in clinically inactive components. Biosimilar manufacturers must also demonstrate that there are no clinically meaningful differences between the biosimilar and the reference product in terms of safety and effectiveness.